IMO the fact that it is being considered as a support to one of the big players drugs is more reassuring than anything. If the efficacy was proving bad as a stand alone, why would it be considered by the NIH/what would be the point in going any further?
I also like the pairing with a Gilead drug + the already existing relationship with Kite - even more fuel to the speculation of a future buyout possibility.
News 
Market Data 
Discover 
AI
